Study #2023-0438
A Phase I/II study of Gilteritinib and Momelotinib for patients with relapsed or refractory FLT3-mutated acute myeloid leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Gilteritinib, Momelotinib
Description
To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloid Leukemia
Study phase:
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-844-926-4785
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.